Tony Hsieh's possible will discovered, sparking wealth questions 4 years after death
The will, written in 2015, was found in the personal belongings of a co-executor of Hsieh's assets in February, records said. The co-executor died that month and was not 'aware' of Hsieh's 2020 death due to an Alzheimer's diagnosis.
Hsieh died in New London, Connecticut, on Friday, Nov. 27, 2020, after being rescued from a fire on Nov. 18. He was 46.
The will, which appears to be signed by Hsieh and others, calls for most of Hsieh's assets to be transferred to a trust. It also orders money to be given to organizations, including Harvard University and the American Red Cross.
Lawyers for Hsieh's estate have repeatedly written in court documents that Hsieh did not have the mental capacity to sign off on contracts in the months and years leading up to his death. It was not immediately clear Friday if the will would hold up in court.
Because no will was located after his death until now, the issue of Hsieh's estate has played out in probate court. Earlier this month, a judge ordered Hsieh's estate to pay his former lawyer hundreds of thousands of dollars as part of a contract signed months before the entrepreneur's death.
Hsieh led retail giant Zappos for 20 years and retired as CEO before his death. He played a pivotal role in the revitalization of downtown Las Vegas and had an estimated net worth in the hundreds of millions of dollars.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
a day ago
- Business Insider
OpenAI's chief research scientist shares the book that inspired him when he was unsure about his career path
OpenAI chief research scientist, Jakub Pachocki, didn't always know he'd be on the front lines of artificial intelligence development. In OpenAI's latest podcast episode, published Friday, Pachocki said he didn't know what he wanted to do with his career as a teenager in high school. He recalled one book that inspired him during those searchful, formative years: "Hackers and Painters" by Y Combinator cofounder Paul Graham. "My dad gave me this book when I was, I think I was like 15, I was pretty unsure of what I wanted to do," Pachocki said. "It was a Polish version of a book by some author I didn't know called 'Hackers and Painters.'" "I found that pretty inspiring," he added. Pachocki joined OpenAI in 2017. He has overseen the development of GPT-4 and replaced OpenAI cofounder Ilya Sutskever as chief scientist in May 2024. "Hackers and Painters" contains a collection of essays from Graham, including one based on a guest lecture he gave at Harvard University about the similarities between hacking and painting. "What hackers and painters have in common is that they're both makers," Graham wrote. "Along with composers, architects, and writers, what hackers and painters are trying to do is make good things. They're not doing research per se, though if in the course of trying to make good things they discover some new technique, so much the better." Having one of the key figures at Sam Altman 's company inspired by Graham is a bit of a full-circle moment. Graham published "Hackers and Painters" in 2004, about a year before the investor co-founded Y Combinator and met 19-year-old Stanford dropout Altman. Altman's startup at the time, Loopt, would be one of the first batch of companies backed by the startup accelerator. In 2009, Graham added Altman to his list of five of the "most interesting startup founders of the last 30 years." Five years later, he chose Altman to take his position as Y Combinator's president. "It's actually very hilarious thinking about it now," Pachocki said. "I didn't really connect the dots."
Business Insider
3 days ago
- Business Insider
Boomer homeowners aren't as well off as you may think
Over a third of older households were cost-burdened in 2023. As the population of Americans 80 and older mushrooms, their housing woes are intensifying. While renters are struggling the most, homeowners are also facing rising costs. If you're a millennial or Gen Zer with a penchant for scrolling Zillow, you've probably found yourself envying the boomer homeowners whose home values have ballooned to prices you could never afford. But many aging households — both renters and homeowners — are struggling with rising housing costs. As the number of older Americans, particularly those in their 80s and older, grows, their housing woes are intensifying. About a third of 65-and-older households were cost-burdened in 2023, meaning they spent more than 30% of their income on housing, according to a new report from Harvard's Joint Center for Housing Studies. More than half of those were severely cost-burdened, spending more than 50% of their income on housing. Household incomes tend to decline as people enter their 80s, when many lose their partners and have to support themselves on a single income. That can make what's often their biggest monthly expense — housing costs — even more difficult to manage. With the oldest baby boomers on the cusp of turning 80, this dynamic is expected to put a lot of additional pressure on accessible housing, long-term care, and other services older people rely on. "We're on the precipice of a pretty big shift in demand," said Jennifer Molinsky, the director of Harvard University's Housing and Aging Society Program. "The share of older adults 65-plus is going to tilt older, and I think a higher share will have cost burdens." Older renters are worse off than homeowners. A majority of them — 58% — were cost-burdened in 2023, most of them severely, the Harvard report found. But homeowners are also increasingly struggling. A growing share of older homeowners — 31% of those in their 80s, as of 2022 — are still saddled with mortgages, and 43% of them are cost-burdened. That's more than twice the share of those without mortgages, the report found. But even those who own their homes outright are still dealing with other ballooning housing costs, including insurance premiums, property taxes, utilities, and home repairs. Love Business Insider? Log into Google and make us a preferred source. The number of older households financially strained by their housing has grown from just over 10 million in 2019 to more than 12.4 million in 2023. Meanwhile, home prices have soared over the last several years, mortgage interest rates are stubbornly high, and smaller, more affordable homes that could be suitable for aging empty-nesters looking to downsize are a shrinking slice of the pie. Just 9% of new homes built in 2023 were under 1,400 square feet. This dynamic is undermining a long American tradition: treating homes as retirement nest eggs. Many homeowners bank on selling their home, downsizing, and living off their sale profits in their older age. But the housing shortage also means that even many homeowners sitting on valuable home equity who want to cash in are having trouble finding somewhere to go. "There just aren't that many smaller condos or apartments that are less expensive that you're going to be able to make that trade off and stay in your community," Molinsky said.
Business Wire
4 days ago
- Business Wire
Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) ('Alpha Cognition' or the 'Company') today announced its financial results for the second quarter ended June 30, 2025. 'The initial ZUNVEYL launch has been met with strong interest from both healthcare providers and patients. Early adoption in nursing homes and by geriatric specialists has created a solid foundation for future growth,' said Michael McFadden, Chief Executive Officer of Alpha Cognition. 'Clinician feedback continues to validate our belief that ZUNVEYL will become an important therapy in the long-term care segment.' Recent Business and Operational Highlights Completed the first quarter of ZUNVEYL commercialization, achieving approximately $2 million in net product revenues year-to-date. Received positive clinician feedback highlighting ZUNVEYL's impact on cognitive function, behavioral symptoms, and its safety profile. Secured the Company's first national Medicare Part D contract with no prior authorization required, ahead of schedule. Sales team engaged with more than 3,700 healthcare professionals and generated prescriptions in over 300 nursing homes. Concluded the Bomb Blast Study, demonstrating that ALPHA-1062 reduced neuroinflammation and neuropathology associated with blast trauma. Second Quarter 2025 Financial Results: ZUNVEYL net product revenues of $1.6 million for the quarter ended June 30, 2025. Research and development expenses for the three months ended June 30, 2025 were $317 thousand compared to $967 thousand for the same period in 2024. Selling, general and administrative expenses for the three months ended June 30, 2025 were $6.5 million compared to $1.4 million for the same period in 2024, driven primarily by commercial-readiness activities. Net operating loss for the three months ended June 30, 2025 were $5.7 million compared to $2.4 million for the same period in 2024. Net loss for the for the three months ended June 30, 2025 were $10.5 million compared to $2.1 million for the same period in 2024, primarily due to a $5.2 million non-cash change in the value of warrant liabilities. Cash and cash equivalents of $39.4 million as of March 31, 2025 compared to $48.6 million as of December 31, 2024. At current utilization rate, the Company expects a cash runway of approximately two years. Following the release, management will host a conference call to review financial and operating results. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury ('mTBI'), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ZUNVEYL's active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. INDICATION AND USAGE ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS ZUNVEYL is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or to any inactive ingredients in ZUNVEYL. Serious skin reactions have occurred. WARNINGS AND PRECAUTIONS Serious Skin Reactions: Serious skin reactions (Stevens-Johnson syndrome and acute generalized exanthematous pustulosis) have been reported in patients receiving galantamine (the active metabolite of ZUNVEYL tablets). If signs or symptoms suggest a serious skin reaction, use of this drug should not be resumed, and alternative therapy should be considered. Anesthesia: See Drug Interactions Section Cardiovascular Conditions: Cholinesterase inhibitors, including ZUNVEYL, have vagotonic effects on the sinoatrial and atrioventricular nodes, leading to bradycardia and AV block. Bradycardia and all types of heart block have been reported in patients taking cholinesterase inhibitors, both with and without known underlying cardiac conduction abnormalities. Therefore, all patients should be considered at risk for adverse effects on cardiac conduction. Patients treated with galantamine up to 24 mg/day using the recommended dosing schedule showed a dose-related increase in risk of syncope. Gastrointestinal Conditions: Cholinesterase inhibitors, including ZUNVEYL, may increase gastric acid secretion. Patients should be monitored closely for active or occult gastrointestinal bleeding, especially those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). Clinical studies of galantamine have shown no increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding. Galantamine has been shown to produce nausea, vomiting, diarrhea, anorexia, and weight loss. Monitor the patient's weight during therapy with ZUNVEYL. Genitourinary Conditions: Although this was not observed in clinical trials with galantamine, cholinesterase inhibitors, including ZUNVEYL, may cause bladder outflow obstruction. Neurological Conditions: Cholinesterase inhibitors are believed to have some potential to cause generalized convulsions. Seizure activity may also be a manifestation of Alzheimer's disease. Patients with Alzheimer's disease should be monitored closely for seizures while taking ZUNVEYL. Pulmonary Conditions: Cholinesterase inhibitors, including ZUNVEYL, should be prescribed with care to patients with a history of severe asthma or obstructive pulmonary disease. Monitor for respiratory adverse reactions. ADVERSE REACTIONS The most common adverse reactions with galantamine tablets (≥5%) were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite. DRUG INTERACTIONS Use with Anticholinergics: Galantamine has the potential to interfere with the activity of anticholinergic medications. Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect is expected when cholinesterase inhibitors are given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol. USE IN SPECIFIC POPULATIONS Pregnancy: Based on animal data may cause fetal harm. Hepatic Impairment: In patients with moderate hepatic impairment, a decrease in clearance of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with severe hepatic impairment is not recommended. Renal Impairment: In patients with a creatinine clearance of 9 to 59 mL/min, an increase in exposure of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with creatinine clearance less than 9 mL/min is not recommended. These are not all of the possible side effects of ZUNVEYL. You can report side effects to the FDA. Visit or call 1‑800‑FDA‑1088. Please click here for Full Prescribing Information. Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'objective,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'target,' 'seek,' 'contemplate,' 'continue' and 'ongoing,' or the negative of these terms, or other comparable terminology intended to identify statements about the future. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company's intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company's filings with Canadian securities regulatory authorities and available at and the Company's filings with the United States Securities and Exchange Commission (the 'SEC'), including those risk factors under the heading 'Risk Factors' in the Company's most recent Annual Report on Form 10-K filed with the SEC on March 31, 2025 and the Company's other filings with the SEC available at These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.
